Find News

Filter articles

Applied Filters

Showing 91 to 100 of 130 results

D’Arcy v Myriad: Australia’s High Court deals blow to natural product patents


Australia’s highest court has said that naturally occurring nucleic acid molecules are not patentable, overturning a lower court ruling.

TPP: Australia succeeds in limiting data exclusivity to five years

Australia, US07-10-2015

Australia’s government has said the period of data exclusivity available for biological drugs in the Trans-Pacific Partnership will be five years, despite pressure from the US to extend it to 12.

Global Pharma IP Forum: Japan’s Supreme Court Teva decision a ‘death sentence’


A Japanese lawyer has described a ruling by the Supreme Court of Japan as a “death sentence” for product-by-process patents and said it is a good time for drugs companies to challenge rivals’ patents.

Pfizer’s Hospira buyout approved in Australia and Canada

Australia, Canada18-08-2015

Pfizer’s $17 billion buyout of Hospira has been approved in Canada and Australia after the countries’ competition bureaus approved the deal.

Pharma patent filings peaked sharply in 2014, report shows

China, International, US04-08-2015

Worldwide applications for pharmaceutical patents “peaked sharply” in 2014, reaching around 28,000, a report has shown.

Biosimilars market value could triple by 2020, says report


The market value for biosimilars around the world could reach $20 billion by the end this year and that figure could nearly triple by 2020, according to a report.

Novartis and Philips talk patents and innovation at Thomson Reuters event


At a Thomson Reuters event in Paris on Thursday to celebrate the European companies featured on its list of top 100 global innovators, panellists including Novartis and Philips discussed the nature of innovation and how to encourage it.

Market for fighting fake pharma packets to soar in value, report says


The global market for products seeking to tackle counterfeit pharmaceutical and cosmetics packaging will reach more than $80 billion by 2020, according to a report.

SIPO rejects Gilead’s Sovaldi patent application


China’s State Intellectual Property Office has rejected Gilead Sciences’s patent application covering its Sovaldi (sofosbuvir) drug after it was challenged by a non-profit group.

BIO 2015: Australia may block gene patents, suggests NZ lawyer

Australia, Canada, EU, New Zealand18-06-2015

Australia could be going down the road of no longer allowing gene patents, New Zealand-based patent lawyer David Nowak said at the BIO International Convention yesterday.

Showing 91 to 100 of 130 results